Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Genflow Biosciences Plc LONDON, Feb. 01, 2024 -- The Company , an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing...

Related Keywords

United Kingdom ,London ,City Of ,Belgium ,Marye Rinella ,Jon Critchley ,Sven Francque ,Bob Roberts ,Eric Leire ,Keith Swann ,Jonathan Paterson ,Genflow Biosciences ,Genflow Bioscience ,Dominic Berger ,Health Products ,Capital Plus Partners Ltd ,Genflow Biosciences Plc ,Contract Development ,Manufacturing Organization ,Financial Conduct Authority ,Agency For Medicines ,Capital Plus Partners Ltd As Joint Broker ,European Medicines Agency ,Genflow Biosciences Ltd ,London Stock Exchange ,Federal Agency ,Joint Broker ,Harbor Access ,Scientific Advisory ,Investigational New Drug ,Orphan Drug Application ,Patent Cooperation Treaty ,United Kingdom Based ,Prospectus Regulation Rules ,Listing Rules ,Disclosure Guidance ,Transparency Rules ,United Kingdom Market Abuse ,London Stock ,Primary Information Provider ,Markets ,